Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo
Abstract
Pancreatic cancer is a malignant digestive system tumor with a particularly poor prognosis, and is the fourth leading cause of cancer‑associated mortality in the USA. The anti‑diabetic therapeutic agent, metformin (MET) has been demonstrated to exert anti‑tumor effects. The present study assessed the ability of MET, alone or in combination with gemcitabine (GEM), to inhibit the growth of the human CFPAC‑1 pancreatic cancer cell line in vitro and in vivo. Cell counting kit‑8 assays were performed to measure CFPAC‑1 cell viability and apoptosis was detected with annexin V/propidium iodide. Cell cycle analysis was conducted by flow cytometry. The mRNA and protein levels of B‑cell lymphoma‑extra large (Bcl‑xL), Bcl2 associated X protein (Bax), caspase‑3, survivin and cyclin D1 in CFPAC‑1 cells and tumor tissues were detected by reverse transcription‑polymerase chain reaction and western blotting, respectively. Furthermore, the expression levels of caspase‑3 and proliferating cell nuclear antigen in tumor tissues were detected by immunohistochemistry. The results demonstrated that following MET treatment, the growth of CFPAC‑1 cells and xenografts in nude mice was inhibited, the expression levels of Bcl‑xL, survivin and cyclin D1 were downregulated, while the expression levels of Bax and caspase‑3 were upregulated. These effects were enhanced when MET was administered in combination with GEM. The mechanism underlying the anti‑tumor effect of MET may be associated with the…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.